Clinical Trials

    AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer's Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer's Disease and Intermediate Amyloid

    Investigator: Juan Toledo Atucha

    Study Coordinator: Jorge Rodriguez Gaytan

    Status: Open Not Enrolling

    ClinicalTrials.gov Number: NCT04468659

    Phone: 346.238.2677

    Protocol Number: PRO00025015

    Description


    The primary purpose of this study is to determine whether treatment with lecanemab is superior to placebo on change from baseline of the Preclinical Alzheimer Cognitive Composite 5 (PACC5) at 216 weeks of treatment (A45 Trial) and to determine whether treatment with lecanemab is superior to placebo in reducing brain amyloid accumulation as measured by amyloid positron emission tomography (PET) at 216 weeks of treatment (A3 Trial).